Tocilizumab significantly reduced 28-day mortality and length of ICU stay in patients with severe COVID-19 pneumonia and low S-spike nAb titers.

The FDA approved Mavyret for the treatment of patients 3 years and older with acute or chronic HCV infection without cirrhosis or with compensated cirrhosis.

The risk of all-cause mortality among older patients with severe CAP was significantly reduced following treatment with glucocorticoids.

More than 460 laid-off employees at the US Centers for Disease Control and Prevention are being rehired, officials said June 11.

Prepandemic severe spirometric obstruction, spirometric restriction, and increased emphysema on CT are linked to higher risk for severe COVID-19.

Researchers found that during 2020 to 2022, tooth disorders accounted for an annual average of 1,944,000 emergency department visits. HealthDay News — Tooth disorders accounted for an annual average ...